Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Derwent London delivers 'another strong leasing performance'

(Sharecast News) - Property investor Derwent London said on Thursday that it had delivered "another strong leasing performance" in FY24, with rental growth driving total returns. Derwent London said gross rental income had grown 0.9% in FY24 to £214.8m, helping the group swing from FY23's pre-tax loss of £475.9m to a pre-tax profit of £116.0m.

Earnings per share were up 4.4% at 106.5p each and the FTSE 250-listed group's FY dividend increased 1.3% year-on-year to 80.5p per share.

Derwent also said estimated rental values had grown 4.3%, while the value of its total property portfolio had increased from £4.65bn to £4.86bn.

Chief executive Paul Williams said: "We have delivered another strong leasing performance, with £18.9m of new rent signed over 12% above ERV. Alongside pre-letting the remaining office space at 25 Baker Street W1, our activity was well distributed across the portfolio. Growth in rental values doubled to 4.3%, the highest level since 2016, and valuations recovered in the second half as yields stabilised, delivering a positive total return of 3.2%.

"Investment volumes are forecast to recover over the coming year, and we expect portfolio ERV growth of 3% to 6% in 2025 which will further drive the group's reversionary profile. Together with development profits from our c.2m sq ft pipeline, this gives us confidence in our total return outlook."

As of 0945 GMT, Derwent shares were down 1.60% at 1,904.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.